Sloy Dahl & Holst LLC Has $856,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Sloy Dahl & Holst LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 4.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 5,411 shares of the company’s stock after purchasing an additional 255 shares during the quarter. Sloy Dahl & Holst LLC’s holdings in Johnson & Johnson were worth $856,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Keener Financial Planning LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $40,000. WFA Asset Management Corp boosted its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $44,000. Disciplined Equity Management Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $45,000. Finally, Grayhawk Investment Strategies Inc. boosted its stake in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on JNJ shares. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. The Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Finally, Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $145.69 on Friday. The company has a market capitalization of $350.63 billion, a PE ratio of 9.08, a P/E/G ratio of 2.43 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a 50 day simple moving average of $147.96 and a two-hundred day simple moving average of $153.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.68 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.40%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.